Обзор рекомендаций пятого Маастрихтского/Флорентийского консенсуса по диагностике и лечению инфекции Helicobacter pylori


Н.В. Захарова, И.Г. Бакулин, В.И. Симаненков, А.А. Маслыгина

ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РФ, Санкт-Петербург
В диагностике и лечении Helicobacter pylori достигнут значительный прогресс, который нашел свое отражение в новой, пятой, редакции доклада Маастрихтского консенсуса. В ходе подготовки к обсуждению пятого Маастрихтского/Флорентийского консенсуса новые данные по H. pylori были рассмотрены 43 специалистами из 24 стран в рамках пяти отдельных секций: 1) Основная и сопутствующая симптоматика (Симптомы/взаимосвязи); 2) Диагностика; 3) Лечение; 4) Профилактика/охрана общественного здоровья; 5) H. pylori и микробиота желудка. Результаты работы отдельных секций представлены для окончательного голосования, включившего всех участников. Рекомендации сформулированы исходя из наиболее достоверных фактических данных и актуальности в лечении Helicobacter pylori в различных клинических ситуациях.

Литература


1. Malfertheiner P., Megraud F., O’Morain C.A., et al. Management of Helicobacter pylori infection – the Maastricht V/ Florence Consensus Report. Gut. 2016;0:1–24.

2. Malfertheiner P., Megraud F., O’Morain C.A., et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646–64.

3. Sugano K., Tack J., Kuipers E.J., et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–67.

4. Захарова, Н.В., Симаненков В.И., Савилова И.В., Сварваль А.В. Helicobacter pylori – изотопная диагностики инфекции и тестирование резистентности. Фарматека. 2016;2:24–27.

5. Ford A.C., Qume M., Moayyedi P., et al. Helicobacter pylori ‘test and treat’ or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology. 2005;128:1838–44.

6. Iijima K., Ohara S., Sekine H., et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut. 2000;46:20–6.

7. Hamada H., Haruma K., Mihara M., et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol. Ther. 2000;14:729–35.

8. Kawanishi M. Development of reflux esophagitis following Helicobacter pylori eradication. J. Gastroenterol. 2005;40:1024–28.

9. Tack J., Talley N.J., Camilleri M., et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466–79.

10. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14–22.

11. Sostres C., Carrera-Lasfuentes P., Benito R., et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am. J. Gastroenterol. 2015;110:684–89.

12. Chan F.K.L., Ching J.Y..L, Suen B.Y., et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144:528–35.

13. Fletcher E.H., Johnston D.E., Fisher C.R., et al. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol. Ther. 2010;32:831–39.

14. Lanas Á., Carrera-Lasfuentes P., Arguedas Y., et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin. Gastroenterol. Hepatol. 2015;13:906–12.e2.

15. Kuipers E.J., Uyterlinde A.M., Peña A.S., et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am. J. Gastroenterol. 1995;90:1401–6.

16. Lundell L., Havu N., Miettinen P., et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol. Ther. 2006;23:639–47.

17. Yaghoobi M., Farrokhyar F., Yuan Y., et al. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am. J. Gastroenterol. 2010;105:1007–13; quiz 1006, 1014.

18. Klinkenberg-Knol E.C., Nelis F., Dent J., et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661–69.

19. Goddard A.F., James M.W., McIntyre A.S., et al. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60:1309–16.

20. Russo G., Miraglia V., Branciforte F., et al. Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study. Pediatr. Blood Cancer. 2011;56:273–78.

21. Franceschi F., Tortora A., Gasbarrini G., et al. Helicobacter pylori and extragastric diseases. Helicobacter. 2014;19(Suppl 1):52–8.

22. Nakamura S., Sugiyama T., Matsumoto T., et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507–13.

23. Ferwana M., Abdulmajeed I., Alhajiahmed A., et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J. Gastroenterol. 2015;21:1305–14.

24. Gisbert J.P., de la Morena F., Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am. J. Gastroenterol. 2006;101:1921–30.

25. Duggan A.E., Elliott C., Logan R.F. Testing for Helicobacter pylori infection: validation and diagnostic yield of a near patient test in primary care. BMJ 1999;319:1236–39.

26. Malfertheiner P. Diagnostic methods for H. pylori infection: choices, opportunities and pitfalls. United Eur. Gastroenterol. J. 2015;3:429–31.

27. el-Zimaity H.M., al-Assi M.T., Genta R.M., et al. Confirmation of successful therapy of Helicobacter pylori infection: number and site of biopsies or a rapid urease test. Am. J. Gastroenterol. 1995;90:1962–64.

28. Osaki T., Mabe K., Hanawa T., et al. Urease-positive bacteria in the stomach induce a false-positive reaction in a urea breath test for diagnosis of Helicobacter pylori infection. J. Med. Microbiol. 2008;57(Pt 7):814–19.

29. Dixon M.F., Genta R.M., Yardley J.H., et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 1996;20:1161–81.

30. Tongtawee T., Dechsukhum C., Leeanansaksiri W., et al. Improved detection of Helicobacter pylori infection and premalignant gastric mucosa using “site specific biopsy”: a randomized control clinical trial. Asian Pac. J. Cancer Prev. 2015;16:8487–90.

31. Jonkers D., Stobberingh E., de Bruine A., et al. Evaluation of immunohistochemistry for the detection of Helicobacter pylori in gastric mucosal biopsies. J. Infect. 1997;35:149–54.

32. Симаненков, В.И., Захарова Н.В., Жебрун А.Б. и соавт. Резистентность Helicobacter pylori к антимикробным препаратам по результатам бактериологического тестирования. Лечащий врач. 2015;4:91–95.

33. Sugimoto M., Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J. Gastroenterol. 2014;20:6400–11.

34. Selgrad M., Meissle J., Bornschein J., et al. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur. J. Gastroenterol. Hepatol. 2013;25:1257–60.

35. Leal Y.A., Flores L.L., García-Cortés L.B., et al. Antibody-based detection tests for the diagnosis of Helicobacter pylori infection in children: a meta-analysis. PloS One. 2008;3:e3751.

36. Sablin O.A., Yurin M., Zakharova N., Simanenkov V. Efficiency of Eradication Therapy in Patients With Autoimmune Gastritis Associated With Helicobacter pylori: A Prospective Study Su1193. Gastroenterology 2014;146;(Suppl. 1):S399.

37. McNicholl A.G., Forné M., Barrio J., et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur. J. Gastroenterol. Hepatol. 2014;26:941–48.

38. Leodolter A., Domínguez-Muñoz J.E., von Arnim U., et al. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am. J. Gastroenterol. 1999;94:2100–104.

39. Vaira D., Vakil N., Menegatti M., et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann. Intern. Med. 2002;136:280–87.

40. Rokkas T., Pistiolas D., Sechopoulos P., et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007;12(Suppl. 2):32–8.

41. Chen H.N., Wang Z., Li X., et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19:166–75.

42. Дехнич Н.Н., Захарова Н.В., Кузьмин-Крутецкий М.И. и соавт. Резолюция экспертного совещания «Тактика ведения пациента с инфекцией HELICOBACTER PYLORI. От простого с сложному». Клин. Микробиол. и антимикроб. химиотер. 2014;6(3):176–80.

43. Thung I., Aramin H., Vavinskaya V., et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol. Ther. 2016;43:514–33.

44. Graham D.Y., Lee Y.C., Wu M.S. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin. Gastroenterol Hepatol. 2014;12:177–86.

45. Симаненков В.И., Захарова Н.В., Савилова И.В. Сравнительное исследование препаратов Де-нол и Новобисмол в схемах эрадикации у пациентов с H. pylori-ассоциированными заболеваниями. Эксперим. и клин. гастроэнтерол 2015;1(113):66–71.

46. Lu H., Zhang W., Graham D.Y. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur. J. Gastroenterol. Hepatol. 2013;25:1134–40.

47. Gatta L., Vakil N., Vaira D., et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587.

48. Feng L., Wen M.Y., Zhu Y.J., et al. Sequential therapy or standard triple therapy for helicobacter pylori infection: an updated systematic review. Am. J. Ther .2016;23:e880–93.

49. Graham D.Y., Lee Y.C., Wu M.S. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin. Gastroenterol. Hepatol. 2014;12:177–86.

50. Cuadrado-Lavín A., Salcines-Caviedes J.R., Diaz-Perez A., et al. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial. J. Antimicrob. Chemother. 2015;70:2376–81.

51. De Francesco V, Hassan C, Ridola L, et al. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J. Med. Microbiol. 2014;63(Pt 5):748–52.

52. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А. и комитет экспертов. Рекомендации Российской гастроэнтеро-логической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнт., гепатол., колопроктол. 2012;22(1):87–9.

53. Захарова Н.В. Автореферат диссертации на соискание ученой степени доктора медицинских наук. Санкт-Петербургская медицинская академия последипломного образования. СПб., 2009.

54. 236 Zhao F., Wang J., Yang Y., et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008;13:532–41.

55. McNicholl A.G., Linares P.M., Nyssen O.P., et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol. Ther. 2012;36:414–25.

56. Graham D.Y. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148:719–31.e3.

57. Gisbert J.P., Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol. Ther. 2006;23:35–44.

58. Di Caro S., Fini L., Daoud Y., et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J. Gastroenterol. 2012;18:5669–78.

59. Liao J., Zheng Q., Liang X., et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18:373–77.

60. Gisbert J.P., Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol. Ther. 2012;35:209–21.

61. Malfertheiner P., Link A., Selgrad M. Helicobacter pylori: perspectives and time trends. Nat. Rev. Gastroenterol. Hepatol. 2014;11:628–38.

62. Gisbert J.P., Barrio J., Modolell I., et al. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis. Sci. 2015;60:458–64.

63. Gisbert J.P. ‘Rescue’ regimens after Helicobacter pylori treatment failure. World J. Gastroenterol. 2008;14:5385–402.

64. IARC/WHO. Helicobacter pylori eradication as a strategy for preventing gastric cancer. International Agency for Research on Cancer/ World Health Organisation, 2014. “http://www.iarc.fr/en/publications/pdfs-online/wrk8/” www.iarc.fr/en/ publications/pdfs-online/wrk8/ (accessed online Aug 2016).

65. Lee Y.C., Chiang T.H., Chou C.K., et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113–1124.e5.

66. Kamada T., Kurose H., Yamanaka Y., et al. Relationship between gastroesophageal junction adenocarcinoma and Helicobacter pylori infection in Japan. Digestion. 2012;85:256–60.

67. Ma J.L., Zhang L., Brown L.M., et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J. Natl. Cancer Inst. 2012;104:488–92.

68. Wong B.C.-Y., Lam S.K., Wong W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.

69. González C.A., Megraud F., Buissonniere A., et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann. Oncol. 2012;23:1320–24.

70. de Martel C., Ferlay J., Franceschi S., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.

71. Lee Y.C., Chen T.H., Chiu H.M., et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676–82.

72. Jung D.H., Kim J.H., Chung H.S., et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis. PLoS One. 2015;10:e0124725.

73. Ford A.C., Forman D., Hunt R.H., et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.

74. Ливзан М.А., Кононов А.В., Мозговой С.И. Течение хронического гастрита, ассоциированного с Helicobacter pylori в постэрадикационном периоде. Эксперим. и клин. Фармакол. 2007;5:116–23.

75. Harvey R.F., Lane J.A., Nair P., et al. Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations – the Bristol Helicobacter Project. Aliment Pharmacol. Ther. 2010;32:394–400.

76. Roderick P., Davies R., Raftery J., et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J. Med. Screen. 2003;10:148–56.

77. Herrero R., Parsonnet J., Greenberg E.R. Prevention of gastric cancer. JAMA. 2014;312:1197–98.

78. Oh S., Kim N., Yoon H., et al. Risk factors of atrophic gastritis and intestinal metaplasia in first-degree relatives of gastric cancer patients compared with age-sex matched controls. J. Cancer. Prev. 2013;18:149–60.

79. Опенко Т.Г, Решетников О.В, Курилович С.А, Симонова Г.И. Рак желудка в Новосибирске на рубеже тысячелетий (тренды заболеваемости и смертности, возможности профилактики). Вопросы онкологии. 2013;6:708–13.

80. Isajevs S., Liepniece-Karele I., Janciauskas D., et al. Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch. 2014;464:403–7.

81. Megraud F. Potential impact of bacterial resistance after population-based Helicobacter pylori treatment. In: Helicobacter pylori eradication as a strategy for preventing gastric cancer. Lyon: IARC, 2014. P. 80–7.

82. Zeng M., Mao X.H., Li J.X., et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1457–64.

83. Andersson A.F., Lindberg M., Jakobsson H., et al. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One. 2008;3:e2836.

84. Yang I., Nell S., Suerbaum S. Survival in hostile territory: the microbiota of the stomach. FEMS Microbiol Rev. 2013;37:736–61.

85. Delgado S., Cabrera-Rubio R., Mira A., et al. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb. Ecol. 2013;65:763–72.

86. Yu G., Gail M.H., Shi J., et al. Association between upper digestive tract microbiota and cancer-predisposing states in the esophagus and stomach. Cancer Epidemiol. Biomarkers Prev. 2014;23:735–41.

87. Engstrand L., Lindberg M. Helicobacter pylori and the gastric microbiota. Best Pract. Res. Clin. Gastroenterol. 2013;27:39–45.

88. Dicksved J., Lindberg M., Rosenquist M., et al. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J. Med. Microbiol. 2009;58(Pt 4):509–16.

89. Aviles-Jimenez F., Vazquez-Jimenez F., Medrano-Guzman R., et al. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci. Rep. 2014;4:4202.

90. Eun C.S., Kim B.K., Han D.S., et al. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter. 2014;19:407–16.

91. Flahou B., Rimbara E., Mori S., et al. The other helicobacters. Helicobacter 2015;20(Suppl. 1):62–7.

92. Liu J., He L., Haesebrouck F., et al. Prevalence of coinfection with gastric non-Helicobacter pylori Helicobacter (NHPH) species in Helicobacter pylori-infected patients suffering from gastric disease in Beijing, China. Helicobacter. 2015;20:284–90.

93. Ladirat S.E., Schols H.A., Nauta A., et al. High-throughput analysis of the impact of antibiotics on the human intestinal microbiota composition. J. Microbiol. Methods. 2013;92:387–97.

94. Захарова, Н.В., Филь Т.С. Высоковирулентный штамм Clostridium difficile в структуре антибиотикоассоциированной диареи в стационаре. Росс. журн. гастроэнтерол., гепатол., колопроктол. 2015;5:46:100.

95. Jernberg C., Löfmark S., Edlund C., et al. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1:56–66.

96. Cox L.M., Blaser M.J. Antibiotics in early life and obesity. Nat. Rev. Endocrinol. 2015;11:182–90.

97. Bailey L.C., Forrest C.B., Zhang P., et al. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr. 2014;168:1063–69.

98. Adamsson I., Edlund C., Nord C.E. Impact of treatment of Helicobacter pylori on the normal gastrointestinal microflora. Clin. Microbiol. Infect. 2000;6:175–77.

99. Jakobsson H., Wreiber K., Fall K., et al. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand. J. Infect. Dis. 2007;39:757–63.

100.Sjölund M., Wreiber K., Andersson D.I., et al. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann. Intern. Med. 2003;139:483–87.

101.Weber S.G., Gold H.S., Hooper D.C., et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerging Infect. Dis. 2003;9:1415–22.

102.Rodríguez-Baño J., Navarro M.D., Romero L., et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Clin. Microbiol. Infect. 2008;14:180–83.

103.Патент №2 24695 Российская Федерация, МПК7 А 61 К 35/74, 33/00, 38/00, 31/732, А 61 Р 104. Способ лечения хронического H. pylori-ассоциированного гастрита препаратом ламинолакт / Симаненков В.И., Суворов А.Н., Захарова Н.В., Боваева Д.И., Соловьева О.И.; заявитель и патентообладатель СПбМАПО (RU). № 002129641/14; заявл. 04.11.02; опубл. 27.02.05, Бюлл. № 6.

104.Lv Z., Wang B., Zhou X., et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp. Ther. Med. 2015;9:707–16.

105.Szajewska H., Horvath A., Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol. Ther. 2015;41:1237–45.


Об авторах / Для корреспонденции


Н.В. Захарова – д.м.н., проф. кафедры терапии и клинической фармакологии ФГБОУ ВО СЗГМУ им. И.И. Мечникова Минздрава РФ; Санкт-Петербург; е-mail: nvzakharova@mail.ru


Похожие статьи


Бионика Медиа